Dimethylarginine dimethylaminohydrolase (DDAH) - A critical regulator of hypertensive left ventricular hypertrophy?

Medical Hypotheses

Volumn 70, Issue 5, 2008, Pages 962-966

  Bai, Yongyi ^a,d   Hui, Rutai ^a,b,c,d  

^a FUWAI HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Sino German Laboratory for Molecular Medicine   (China)

^d PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLARGININASE; NITRIC OXIDE SYNTHASE;

ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; PRIORITY JOURNAL; URINARY EXCRETION;

AMIDOHYDROLASES; ANIMALS; ARGININE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; ENDOTHELIUM; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MICE; MODELS, BIOLOGICAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RISK; RISK FACTORS;

EID: 40849116791     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.08.028     Document Type: Article

References (38)

1. World Health Report 2002. Reducing risks, promoting healthy life. Geneva: World Health Organization; 2002.
2. Murray C.J.L., and Lopez A.D. The global burden of disease (1996), Harvard School of Public Health, Cambridge (MA)
3. Howell S.J., Sear J.W., and Foëx P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Brit J Anaesth 92 4 (2004) 570-583
4. Lorell B.H., and Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102 (2000) 470-479
5. Schmieder R.E., and Messerli F.H. Hypertension and the heart. J Hum Hypertens 14 (2000) 597
6. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
7. Joseph A.D., and Robert A.P. Hypertensive heart disease. Hypertens Res 28 (2005) 191-202
8. Kaplan N.M. Systemic hypertension: mechanisms and diagnosis. Braunwald's heart disease: a textbook of cardiovascular medicine. 7th ed. (2005), Elsevier Saunders, USA
9. Deschepper C.F., Boutin-Ganache I., Zahabi A., et al. In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension 39 (2002) 332-336
10. Perticone F., Sciacqua A., Maio R., et al. Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46 3 (2005) 518-523
11. Boger R.H. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 10 Suppl 1 (2005) 19-25
12. Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 31 (1998) 189-193
13. G-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 264 (1989) 10205-10209
14. Toth J., Racz A., Kaminski P.M., et al. Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone. Hypertension 49 3 (2007) 563-568
15. Rawal N., Rajpurohit R., Lischwe M.A., et al. Structural specificity of substrate for S-adenosylmethionine:protein arginine N-methyltransferases. Biochim Biophys Acta 1248 (1995) 11-18
16. Leiper J., Nandi M., Torondel B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13 2 (2007) 198-203
17. Szuba A., and Podgorski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor - evidence from epidemiological and prospective clinical trials. Pharmacol Rep 58 Suppl (2006) 16-20
18. Suda O., Tsutsui M., Morishita T., et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of reninangiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24 (2004) 1682-1688
19. Achan V., Broadhead M., Malaki M., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler ThrombVasc Biol 23 (2003) 1455-1459
20. Kielstein J.T., Bode-Boger S.M., Klein G., et al. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 33 (2003) 370-375
21. Kielstein J.T., Impraim B., Simmel S., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004) 172-177
22. Kielstein J.T., Donnerstag F., Gasper S., et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37 8 (2006) 2024-2029
23. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
24. Valkonen V.P., Paiva H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
25. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97 (2005) e53-e59
26. Schulze F., Lenzen H., Hanefeld C., et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 152 3 (2006) 493.e1-493.e8
27. Meinitzer A., Seelhorst U., Wellnitz B., et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 53 2 (2007) 273-283
28. Devereux R.B., and Dahlof B. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Curr Med Res Opin 23 2 (2007) 443-457
29. Gradman A.H., and Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 48 5 (2006) 326-341
30. Zhou M.S., Adam A.G., Jaimes E.A., et al. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 42 5 (2003) 945-951
31. Sladek T., Gerova M., Znojil V., et al. Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase. Physiol Res 45 (1996) 335-338
32. Zoccali C., Mallamaci F., Maas R., et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62 (2002) 339-345
33. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med 10 Suppl 1 (2005) 49-57
34. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2 4 (2006) 209-220
35. Jiang D.J., Jiang J.L., Tan G.S., et al. Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 600-606
36. MacAllister R.J., Parry H., Kimoto M., et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 119 (1996) 1533-1540
37. Smith C.L., Birdsey G.M., Anthony S., et al. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 308 (2003) 984-989
38. Dayoub H., Achan V., Adimoolam S., et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108 (2003) 3042-3047